141 related articles for article (PubMed ID: 35064675)
21. Successful treatment of refractory prurigo nodularis with baricitinib.
Yin M; Wu R; Chen J; Dou X
Dermatol Ther; 2022 Aug; 35(8):e15642. PubMed ID: 35708292
[No Abstract] [Full Text] [Related]
22. Successful treatment of generalized granuloma annulare with baricitinib.
Yan TM; Zhang H; Wu XY; Zhang ZY
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e500-e502. PubMed ID: 35220615
[No Abstract] [Full Text] [Related]
23. Repigmentation of vitiligo with oral baricitinib.
Mumford BP; Gibson A; Chong AH
Australas J Dermatol; 2020 Nov; 61(4):374-376. PubMed ID: 32491188
[No Abstract] [Full Text] [Related]
24. Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis.
Koh YG; Han HS; Seok J; Choi SY; Li K; Kim BJ; Yoo KH
Skin Res Technol; 2023 Aug; 29(8):e13425. PubMed ID: 37632179
[No Abstract] [Full Text] [Related]
25. Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib.
De Stefano L; Bobbio-Pallavicini F; Montecucco C; Bugatti S
Rheumatology (Oxford); 2022 Mar; 61(3):e64-e66. PubMed ID: 34647989
[No Abstract] [Full Text] [Related]
26. What is the full potential of baricitinib in treating patients with COVID-19?
Biddle K; White J; Sofat N
Expert Rev Clin Immunol; 2022 Jun; 18(6):545-549. PubMed ID: 35486502
[No Abstract] [Full Text] [Related]
27. JAK Inhibition with Baricitinib for Severe CVID-Related Enteropathy: a Case Report.
Abdelmoumen A; van Montfrans J; van Wijk F; Leavis H
J Clin Immunol; 2023 Nov; 43(8):1766-1769. PubMed ID: 37612576
[No Abstract] [Full Text] [Related]
28. Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line-field confocal optical coherence tomography evaluation.
Verzì AE; Lacarrubba F; Dall'Oglio F; Rini S; Tosti A; Micali G
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e459-e461. PubMed ID: 37909307
[No Abstract] [Full Text] [Related]
29. Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report.
Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol; 2021 Sep; 48(9):e472-e473. PubMed ID: 34151450
[No Abstract] [Full Text] [Related]
30. Improvement of chronic nodular prurigo with baricitinib.
Pereira MP; Zeidler C; Ständer S
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e486-e488. PubMed ID: 35138657
[No Abstract] [Full Text] [Related]
31. [In patients hospitalized for COVID-19, does baricitinib reduce 28-days mortality compared to standard treatment, and is it safe?].
Lanthier L; Plourde MÉ; Cauchon M
Rev Med Interne; 2022 Oct; 43(10):634-635. PubMed ID: 36123199
[No Abstract] [Full Text] [Related]
32. Successful treatment of refractory folliculitis decalvans with secukinumab.
Ismail FF; Sinclair R
Australas J Dermatol; 2020 May; 61(2):165-166. PubMed ID: 31646619
[No Abstract] [Full Text] [Related]
33. Treatment of Progressive Nodular Histiocytosis With Baricitinib.
Huang Y; Zhang Z; Zhu L; Chen Y
JAMA Dermatol; 2022 Mar; 158(3):325-327. PubMed ID: 35044417
[No Abstract] [Full Text] [Related]
34. Baricitinib is a potential treatment in inflammatory osteoarthritis: a proof of concept study.
Wang Q; Chen Z; Dai SM
Rheumatology (Oxford); 2022 Aug; 61(8):e213-e215. PubMed ID: 35262662
[No Abstract] [Full Text] [Related]
35. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib.
Moussa A; Colla T; Morrison B; Sinclair R
Australas J Dermatol; 2022 May; 63(2):276-277. PubMed ID: 35213737
[No Abstract] [Full Text] [Related]
36. Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients.
Numata T; Irisawa R; Mori M; Uchiyama M; Harada K
Acta Derm Venereol; 2024 Jan; 104():adv18348. PubMed ID: 38248913
[No Abstract] [Full Text] [Related]
37. Treatment of Severe Nail Lichen Planus With Baricitinib.
Pünchera J; Laffitte E
JAMA Dermatol; 2022 Jan; 158(1):107-108. PubMed ID: 34878494
[No Abstract] [Full Text] [Related]
38. Pilot study of baricitinib for active Sjogren's syndrome.
Bai W; Liu H; Dou L; Yang Y; Leng X; Li M; Zhang W; Zhao Y; Zeng X
Ann Rheum Dis; 2022 Jul; 81(7):1050-1052. PubMed ID: 35338034
[No Abstract] [Full Text] [Related]
39. [Dapsone treatment of folliculitis decalvans].
Paquet P; Piérard GE
Ann Dermatol Venereol; 2004 Feb; 131(2):195-7. PubMed ID: 15026749
[TBL] [Abstract][Full Text] [Related]
40. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
Kim H; Dill S; O'Brien M; Vian L; Li X; Manukyan M; Jain M; Adeojo LW; George J; Perez M; Grom AA; Sutter M; Feldman BM; Yao L; Millwood M; Brundidge A; Pichard DC; Cowen EW; Shi Y; Lu S; Tsai WL; Gadina M; Rider LG; Colbert RA
Ann Rheum Dis; 2021 Mar; 80(3):406-408. PubMed ID: 32843325
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
